# PDUFA dates May 2026: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2026-05

> 516 FDA catalysts are dated in May 2026, including 7 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in May 2026?

PDUFA dates in May 2026: VYVGART (efgartigimod, ARGX) on May 10, 2026; Zai Lab Ltd (ZLAB) on May 10, 2026; LEQEMBI (lecanemab, BIIB) on May 24, 2026; Afrezza (afrezza, MNKD) on May 29, 2026; MANNKIND CORP (MNKD) on May 29, 2026; indegene (CING) on May 31, 2026; and 1 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2026-05)

Source: Press release filed with the SEC (EX-99), accession 0001697862-26-000030, https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm (retrieved 2026-11-12). Last confirmed 2026-05-07. Cite: https://sec-api.dev/fda-calendar/2026-05#answer

## PDUFA dates in May 2026

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| May 10, 2026 | ARGENX SE | ARGX | VYVGART (efgartigimod) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm) |
| May 10, 2026 | Zai Lab Ltd | ZLAB |  | with acetylcholine receptor antibody | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm) |
| May 24, 2026 | BIOGEN INC. | BIIB | LEQEMBI (lecanemab) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504526000045/biib-20260331.htm) |
| May 29, 2026 | MANNKIND CORP | MNKD | Afrezza (afrezza) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/mnkd-ex99_1.htm) |
| May 29, 2026 | MANNKIND CORP | MNKD |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/899460/000119312526208916/mnkd-20260331.htm) |
| May 31, 2026 | Cingulate Inc. | CING | indegene |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm) |
| May 31, 2026 | Cingulate Inc. | CING |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/ex99-1.htm) |

## All catalysts in May 2026

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 1, 2026 | [Reproxalap NDA/BLA submission](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease and | completed | "On May 1, 2026, Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") released an updated corporate overview presentation (the "Corporate Overview") which, among other things, disclosed (i) standardized treatment estimates and confidence intervals for the primary endpoints of all proposed commercial dosing regimen efficacy clinical trials of reproxalap submitted to the New Drug Application for the treatment of dry eye disease and (ii) Aldeyra's abbreviated interpretations of the U.S. Food & Drug Administration positions on the primary endpoints for the reproxalap clinical trials, as well as the Aldeyra positions on the primary endpoints." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526199157/aldx-20260501.htm)) |
| May 1, 2026 | [Revtorpyk (gedatolisib) topline data readout](https://sec-api.dev/pdufa/gedatolisib) | FTH |  | completed, met | "In addition, on May 1, 2026, Celcuity announced positive topline results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 trial, with both the gedatolisib triplet (gedatolisib plus fulvestrant plus palbociclib) and the gedatolisib doublet (gedatolisib plus fulvestrant) demonstrating statistically significant and clinically meaningful improvements in progression-free survival." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1829802/000119312526225333/snse-20260331.htm)) |
| May 1, 2026 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000057/exhibit9912026q1pressrelea.htm)) |
| May 1, 2026 | [Zytiga (abiraterone) FDA advisory committee meeting](https://sec-api.dev/pdufa/abiraterone) | AZN |  | completed | "ODAC overwhelming majority voted that Truqap plus abiraterone and ADT demonstrated a favourable benefit risk profile for patients based on the CAPItello-281 Phase III trial results" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426004226/a7026c.htm)) |
| May 1, 2026 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/e665435_ex99-1.htm)) |
| May 1, 2026 | [Mirikizumab iv primary completion](https://sec-api.dev/pdufa/mirikizumab-iv) | LLY | Ulcerative Colitis | completed | "NCT05784246 (A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-01 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05784246)) |
| May 1, 2026 | [Mevidalen primary completion](https://sec-api.dev/pdufa/mevidalen) | LLY | Alzheimer Disease | completed | "NCT06538116 (A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-01 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06538116)) |
| May 1, 2026 | [Bezisterim primary completion](https://sec-api.dev/pdufa/bezisterim) | BIVI | Parkinsons Disease (PD) | completed | "NCT06757010 (A Study of NE3107 in Early Parkinson's): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-01 (ACTUAL); Lead Sponsor BioVie Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06757010)) |
| May 1, 2026 | [Bnt162b2 (2025/2026 recommended sars-cov-2 strain) primary completion](https://sec-api.dev/pdufa/bnt162b2-2025-2026-recommended-sars-cov-2-strain) | BNTX | COVID-19; SARS-COV-2 Infection | completed | "NCT07069309 (A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-01 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07069309)) |
| May 1, 2026 | [Menacyw conjugate vaccine primary completion](https://sec-api.dev/pdufa/menacyw-conjugate-vaccine) | SNY | Meningococcal Infection; Healthy Volunteers | completed | "NCT07135986 (Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-01 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07135986)) |
| May 1, 2026 | [JAKAFI (ruxolitinib) FDA approval](https://sec-api.dev/pdufa/ruxolitinib) | INCY |  | completed, approved | "NDA217180 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260501, review_priority STANDARD; sponsor_name INCYTE CORP; product JAKAFI XR (RUXOLITINIB PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217180%22)) |
| May 2, 2026 | [TherapeuticsMD, Inc. earnings report](https://sec-api.dev/companies/txmd/catalysts) | TXMD |  | completed | "PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED MAY 12, 2026, ENTITLED "THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/25743/000121390026055070/ea028977601ex99-1.htm)) |
| May 2, 2026 | [Bremzalerbart primary completion](https://sec-api.dev/pdufa/bremzalerbart) | REGN | Allergic Conjunctivitis | withdrawn | "NCT07309432 (Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-05-02 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07309432)) |
| May 4, 2026 | [Cryoport, Inc. earnings report](https://sec-api.dev/companies/cyrx/catalysts) | CYRX |  | completed | "Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124524/000110465926054942/tm2613494d1_ex99-1.htm)) |
| May 4, 2026 | [Twist Bioscience Corp earnings report](https://sec-api.dev/companies/twst/catalysts) | TWST |  | completed | "Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581280/000158128026000037/twst-2026331xex991.htm)) |
| May 4, 2026 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm)) |
| May 4, 2026 | [Oric Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/oric/catalysts) | ORIC |  | completed | "ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526203993/oric-ex99_1.htm)) |
| May 4, 2026 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526204056/d132166dex991.htm)) |
| May 4, 2026 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "SAN RAFAEL, Calif., May 4, 2026 - BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the first quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000006/earningsrelease-4may26ex991.htm)) |
| May 4, 2026 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-ex99_1.htm)) |
| May 4, 2026 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/ex-991_q12026.htm)) |
| May 4, 2026 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/adct-20260331pressrelease.htm)) |
| May 4, 2026 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000044/a2026q1bhvnearningsprex991.htm)) |
| May 4, 2026 | [Expansion label expansion decision](https://sec-api.dev/pdufa/expansion) | ADMA |  | completed, approved | "On May 4, 2026, ADMA Biologics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved the Company's label expansion supplemental Biologics License Application for ASCENIVTM to include pediatric immune compromised patients two years of age and older." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1368514/000114036126018667/ef20072196_8k.htm)) |
| May 4, 2026 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/a2026q1_8-kxex991.htm)) |
| May 4, 2026 | [CRISPR Therapeutics AG earnings report](https://sec-api.dev/companies/crsp/catalysts) | CRSP |  | completed | "CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1674416/000119312526204147/crsp-ex99_1.htm)) |
| May 4, 2026 | [Nucala (mepolizumab) topline data readout](https://sec-api.dev/pdufa/mepolizumab) | GSK | Hypereosinophilic Syndrome | completed | "NCT04965636 (Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04965636?tab=results)) |
| May 4, 2026 | [Navacaprant primary completion](https://sec-api.dev/pdufa/navacaprant) | NMRA | Major Depressive Disorder | completed | "NCT06058039 (Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-04 (ACTUAL); Lead Sponsor Neumora Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06058039)) |
| May 4, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | completed | "NCT06606847 (A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-04 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06606847)) |
| May 5, 2026 | [Trevi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trvi/catalysts) | TRVI |  | completed | "Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1563880/000119312526206382/trvi-ex99_1.htm)) |
| May 5, 2026 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm)) |
| May 5, 2026 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "Rigel Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000033/rigl-20260505xex991q12026r.htm)) |
| May 5, 2026 | [OnKure Therapeutics, Inc. earnings report](https://sec-api.dev/companies/okur/catalysts) | OKUR |  | completed | "OnKure Therapeutics Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1637715/000119312526206396/okur-ex99_1.htm)) |
| May 5, 2026 | [KEYTRUDA® (pembrolizumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/pembrolizumab) | PFE | muscle-invasive bladder cancer | completed | "Pfizer and Astellas Pharma Inc. announced the FDA accepted for priority review a sBLA for perioperative (before and after surgery) Padcev in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as treatment for patients with muscle-invasive bladder cancer (MIBC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm)) |
| May 5, 2026 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/cogt-ex99_1.htm)) |
| May 5, 2026 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312526205009/d155025dex991.htm)) |
| May 5, 2026 | [MYQORZO® (aficamten) topline data readout](https://sec-api.dev/pdufa/aficamten) | CYTK |  | completed, positive | "On May 5, 2026, we announced positive topline results from ACACIA-HCM." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm)) |
| May 5, 2026 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000036/sdgr-20260331x8kxexx991.htm)) |
| May 5, 2026 | [PRECISION BIOSCIENCES INC earnings report](https://sec-api.dev/companies/dtil/catalysts) | DTIL |  | completed | "Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1357874/000162828026030123/dtil-20260505ex991.htm)) |
| May 5, 2026 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "(NASDAQ: OCUL, "Ocular"), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_ex99-1.htm)) |
| May 5, 2026 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/a1q26financialpr.htm)) |
| May 5, 2026 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526205187/iron-ex99_1.htm)) |
| May 5, 2026 | [Editas Medicine, Inc. earnings report](https://sec-api.dev/companies/edit/catalysts) | EDIT |  | completed | "Editas Medicine Announces First Quarter 2026 Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000043/editasmedicinepressrelease.htm)) |
| May 5, 2026 | [REPLIGEN CORP earnings report](https://sec-api.dev/companies/rgen/catalysts) | RGEN |  | completed | "Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/730272/000119312526205011/rgen-ex99_1.htm)) |
| May 5, 2026 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000051/spyre-20260331xexx991.htm)) |
| May 5, 2026 | [GOG-3147 trial start](https://sec-api.dev/pdufa/gog-3147) | ZNTL | Cyclin E1-positive platinum-resistant ovarian cancer | completed | "SAN DIEGO — May 5, 2026 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that the first patient has been dosed in the Phase 3 ASPENOVA clinical trial (NCT07546500, GOG-3147, ENGOT-ov109, APGOT-OV27) evaluating azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1725160/000172516026000033/aspenovafpipressrelease.htm)) |
| May 5, 2026 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026030136/q12026earningspr_draft.htm)) |
| May 5, 2026 | [STANDARD BIOTOOLS INC. earnings report](https://sec-api.dev/companies/lab/catalysts) | LAB |  | completed | "Standard BioTools Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1162194/000119312526206395/lab-ex99_1.htm)) |
| May 5, 2026 | [Relay Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rlay/catalysts) | RLAY |  | completed | "Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1812364/000119312526206398/rlay-ex99_1.htm)) |
| May 5, 2026 | [Bempikibart trial start](https://sec-api.dev/pdufa/bempikibart) | QTTB |  | completed | ""There is significant demand from patients in Part B for continued dosing after the post-treatment follow-up period, and we are thrilled to announce that the first patient has been dosed in the OLE portion of Part B. Alongside this progress, we raised gross proceeds of $10.5 million through a registered direct offering and gross proceeds of $14.2 million via our ATM program, further strengthening our financial position."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661998/000119312526205006/qttb-ex99_1.htm)) |
| May 5, 2026 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/d149508dex991.htm)) |
| May 5, 2026 | [Azenosertib trial start](https://sec-api.dev/pdufa/azenosertib) | ZNTL | Cyclin E1-Positive Platinum-Resistant Ovarian Cancer | completed | "Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1725160/000172516026000033/aspenovafpipressrelease.htm)) |
| May 5, 2026 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312526205008/alks-ex99_1.htm)) |
| May 5, 2026 | [Q32 Bio Inc. earnings report](https://sec-api.dev/companies/qttb/catalysts) | QTTB |  | completed | "Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661998/000119312526205006/qttb-ex99_1.htm)) |
| May 5, 2026 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "SAN DIEGO, May 5, 2026 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/q1-2026xearningsrelease.htm)) |
| May 5, 2026 | [IQVIA HOLDINGS INC. earnings report](https://sec-api.dev/companies/iqv/catalysts) | IQV |  | completed | "IQVIA Reports First-Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478242/000162828026030118/iqv-q1x2026earningspressre.htm)) |
| May 5, 2026 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | ""the Company") today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926055629/tm2613550d1_ex99-1.htm)) |
| May 5, 2026 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported first quarter 2026 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/tm2613584d1_ex99-1.htm)) |
| May 5, 2026 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/qure-20260505xex99d1.htm)) |
| May 5, 2026 | [Nuvectis Pharma, Inc. earnings report](https://sec-api.dev/companies/nvct/catalysts) | NVCT |  | completed | "Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1875558/000110465926055264/tm2613389d1_ex99-1.htm)) |
| May 5, 2026 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526206368/rare-ex99_1.htm)) |
| May 5, 2026 | [Zanzalintinib trial start](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | recurrent Grade I/II/III meningioma with relapse or progression | completed | "Today, Exelixis announced it has initiated STELLAR-201, a phase 2 trial evaluating zanzalintinib in patients with recurrent Grade I/II/III meningioma with relapse or progression following radiation and/or surgery or those who are not candidates for these therapies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm)) |
| May 5, 2026 | [Dianthus Therapeutics, Inc. /DE/ earnings report](https://sec-api.dev/companies/dnth/catalysts) | DNTH |  | completed | "AND REPORTS Q1 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-ex99_1.htm)) |
| May 5, 2026 | [Elegrobart topline data readout](https://sec-api.dev/pdufa/elegrobart) | VRDN |  | completed, positive | "WALTHAM, Mass. - (BUSINESS WIRE) - Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced positive topline data from the REVEAL-2 phase 3 clinical trial of elegrobart in patients with chronic thyroid eye disease (TED)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977dex991.htm)) |
| May 5, 2026 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526204944/idya-ex99_1.htm)) |
| May 5, 2026 | [Adaptive Biotechnologies Corp earnings report](https://sec-api.dev/companies/adpt/catalysts) | ADPT |  | completed | "Adaptive Biotechnologies Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478320/000119312526206455/adpt-ex99_1.htm)) |
| May 5, 2026 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-ex99_1.htm)) |
| May 5, 2026 | [Abdakibart topline data readout](https://sec-api.dev/pdufa/abdakibart) | AVTX | hidradenitis suppurativa | completed, positive | "•On May 5, 2026, Avalo reported positive topline Phase 2 LOTUS results for abdakibart in adults with moderate to severe HS." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000032/ex-9911q2026earningsrelease.htm)) |
| May 5, 2026 | [Bezuclastinib NDA/BLA acceptance](https://sec-api.dev/pdufa/bezuclastinib) | COGT | NonAdvanced Systemic Mastocytosis | completed | "Announced the FDA accepted its NDA for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/cogt-ex99_1.htm)) |
| May 5, 2026 | [Compass Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cmpx/catalysts) | CMPX |  | completed | "Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326003005/exh_991.htm)) |
| May 5, 2026 | [MIMRYLO™ (rusfertide) NDA/BLA acceptance](https://sec-api.dev/pdufa/rusfertide) | PTGX |  | completed | "March 2, Takeda and Protagonist announced that the U.S. FDA accepted the New Drug Application for rusfertide and granted" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926055629/tm2613550d1_ex99-1.htm)) |
| May 5, 2026 | [Theriva Biologics, Inc. earnings report](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed | "Biologics Reports First Quarter 2026 Operational Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_ex99-1.htm)) |
| May 5, 2026 | [Arcus Biosciences, Inc. earnings report](https://sec-api.dev/companies/rcus/catalysts) | RCUS |  | completed | "Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000032/a2026q18kexhibit991.htm)) |
| May 5, 2026 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000162828026030522/q120268kex991.htm)) |
| May 5, 2026 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm)) |
| May 2026 | [Rp-l102 primary completion](https://sec-api.dev/pdufa/rp-l102) | RCKT | Fanconi Anemia Complementation Group A | delayed | "NCT04248439 (Gene Therapy for Fanconi Anemia, Complementation Group A): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-05 (ESTIMATED); Lead Sponsor Rocket Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04248439)) |
| May 6, 2026 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000119312526209044/d54063dex991.htm)) |
| May 6, 2026 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/exhibit991-33126earningspr.htm)) |
| May 6, 2026 | [ZEVRA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/zvra/catalysts) | ZVRA |  | completed | "Zevra Reports First Quarter 2026 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000029/zvra-20260506xex991earnings.htm)) |
| May 6, 2026 | [Taysha Gene Therapies, Inc. earnings report](https://sec-api.dev/companies/tsha/catalysts) | TSHA |  | completed | "Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526207633/d99032dex991.htm)) |
| May 6, 2026 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/vnda8-k562026exhibit991.htm)) |
| May 6, 2026 | [DiaMedica Therapeutics Inc. earnings report](https://sec-api.dev/companies/dmac/catalysts) | DMAC |  | completed | "Minneapolis, Minnesota - May 6, 2026 (Business Wire) - DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today provided a business update and reported financial results for the quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401040/000143774926015218/ex_957479.htm)) |
| May 6, 2026 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports first quarter financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036126019205/ef20072537_ex99-1.htm)) |
| May 6, 2026 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184326003052/exh_991.htm)) |
| May 6, 2026 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000082/mlys2026q18kex991.htm)) |
| May 6, 2026 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036126019295/ef20072554_ex99-1.htm)) |
| May 6, 2026 | [TScan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tcrx/catalysts) | TCRX |  | completed | "TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783328/000119312526207549/tcrx-ex99_1.htm)) |
| May 6, 2026 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/mirm-20260506xexx991.htm)) |
| May 6, 2026 | [Vaxcyte, Inc. earnings report](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | completed | "Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/pcvx-20260506xexx991.htm)) |
| May 6, 2026 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "MannKind Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526208910/mnkd-ex99_1.htm)) |
| May 6, 2026 | [Elanco Animal Health Inc earnings report](https://sec-api.dev/companies/elan/catalysts) | ELAN |  | completed | "Elanco Animal Health Reports First Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739104/000173910426000027/elanco-20260331exhibit991.htm)) |
| May 6, 2026 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/acad-ex99_1.htm)) |
| May 6, 2026 | [Vir Biotechnology, Inc. earnings report](https://sec-api.dev/companies/vir/catalysts) | VIR |  | completed | "Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1706431/000162828026031273/a20260506-q1ex991earningsr.htm)) |
| May 6, 2026 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/exhibit991tarsus562026.htm)) |
| May 6, 2026 | [BRIUMVI® (ublituximab) earnings report](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed | "TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm)) |
| May 6, 2026 | [Zomedica Corp. earnings report](https://sec-api.dev/companies/zomdf/catalysts) | ZOMDF |  | completed | "ANN ARBOR, MI / ACCESSWIRE / May 6, 2026 / Zomedica Corp. (OTCQB: ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the first quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1684144/000165495426004419/zom_ex991.htm)) |
| May 6, 2026 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000162828026030866/exhibit991-q12026earningsr.htm)) |
| May 6, 2026 | [Attruby (acoramidis) earnings report](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed | "PALO ALTO, Calif., May 7, 2026 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the first quarter ended March 31, 2026, and provided an update on Attruby's commercial progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000018/bbio-2026331xex991.htm)) |
| May 6, 2026 | [PHIBRO ANIMAL HEALTH CORP earnings report](https://sec-api.dev/companies/pahc/catalysts) | PAHC |  | completed | "Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069899/000110465926056316/pahc-20260506xex99d1.htm)) |
| May 6, 2026 | [Tenaya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tnya/catalysts) | TNYA |  | completed | "Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858848/000119312526208975/tnya-ex99_1.htm)) |
| May 6, 2026 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "Royalty Pharma reports first quarter 2026 results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm)) |
| May 6, 2026 | [PERRIGO Co plc earnings report](https://sec-api.dev/companies/prgo/catalysts) | PRGO |  | completed | "Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000044/cy26q1ex991pressrelease.htm)) |
| May 6, 2026 | [Xencor Inc earnings report](https://sec-api.dev/companies/xncr/catalysts) | XNCR |  | completed | "Xencor Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000042/xncr-20260506xexx991.htm)) |
| May 6, 2026 | [ZUSDURI (mitomycin) earnings report](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/ex_956006.htm)) |
| May 6, 2026 | [Lyell Immunopharma, Inc. earnings report](https://sec-api.dev/companies/lyel/catalysts) | LYEL |  | completed | "Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806952/000162828026031269/lyel-20260506x8kexx991.htm)) |
| May 6, 2026 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312526208966/srpt-ex99_1.htm)) |
| May 6, 2026 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports First Quarter Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000077/exhibit991-q0126.htm)) |
| May 6, 2026 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports First Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/nvaxq1-26earningspressrele.htm)) |
| May 6, 2026 | [Surrozen, Inc./DE earnings report](https://sec-api.dev/companies/srzn/catalysts) | SRZN |  | completed | "Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824893/000119312526208999/srzn-ex99_1.htm)) |
| May 6, 2026 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000021/uthrq12026-ex991.htm)) |
| May 6, 2026 | [LIFECORE BIOMEDICAL, INC. \DE\ earnings report](https://sec-api.dev/companies/lfcr/catalysts) | LFCR |  | completed | "Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000018/lfcr-2026q1xex991earningsr.htm)) |
| May 6, 2026 | [BIO-TECHNE Corp earnings report](https://sec-api.dev/companies/tech/catalysts) | TECH |  | completed | "Minneapolis/May 6, 2026/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/842023/000110465926055887/tech-20260506xex99d1.htm)) |
| May 6, 2026 | [Lifevantage Corp earnings report](https://sec-api.dev/companies/lfvn/catalysts) | LFVN |  | completed | "LifeVantage Announces Financial Results for the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/849146/000119312526208934/lfvn-ex99_1.htm)) |
| May 6, 2026 | [Revolution Medicines, Inc. earnings report](https://sec-api.dev/companies/rvmd/catalysts) | RVMD |  | completed | "Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1628171/000119312526208918/rvmd-ex99_1.htm)) |
| May 6, 2026 | [Navacaprant primary completion](https://sec-api.dev/pdufa/navacaprant) | NMRA | Major Depressive Disorder | completed | "NCT06058013 (Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-06 (ACTUAL); Lead Sponsor Neumora Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06058013)) |
| May 6, 2026 | [Livdelzi® (seladelpar) primary completion](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cholangitis | completed | "NCT06060665 (Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-06 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06060665)) |
| May 6, 2026 | [Baloncibart primary completion](https://sec-api.dev/pdufa/baloncibart) | REGN | Postural Orthostatic Tachycardia Syndrome (POTS) | completed | "NCT06593600 (Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-06 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06593600)) |
| May 6, 2026 | [Barzolvolimab primary completion](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Atopic Dermatitis | completed | "NCT06727552 (A Study of Barzolvolimab in Patients With Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-06 (ACTUAL); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06727552)) |
| May 7, 2026 | [Bictegravir NDA/BLA acceptance](https://sec-api.dev/pdufa/bictegravir) | GILD |  | completed | "•Announced U.S. Food and Drug Administration ("FDA") accepted New Drug Application for bictegravir and lenacapavir ("BIC/LEN") for virologically suppressed people with HIV under priority review, with a Prescription Drug User Fee Act ("PDUFA") target action date of August 27, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm)) |
| May 7, 2026 | [OmniAb, Inc. earnings report](https://sec-api.dev/companies/oabi/catalysts) | OABI |  | completed | "OmniAb Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1846253/000184625326000035/a2026q1ex991.htm)) |
| May 7, 2026 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000166118126000007/orgo-ex99_1.htm)) |
| May 7, 2026 | [Prime Medicine, Inc. earnings report](https://sec-api.dev/companies/prme/catalysts) | PRME |  | completed | "Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1894562/000162828026031719/q120268-kex991xpressrelease.htm)) |
| May 7, 2026 | [Camp4 Therapeutics Corp earnings report](https://sec-api.dev/companies/camp/catalysts) | CAMP |  | completed | "CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736730/000162828026032096/camp4reportsfirstquarter20.htm)) |
| May 7, 2026 | [COGNITION THERAPEUTICS INC earnings report](https://sec-api.dev/companies/cgtx/catalysts) | CGTX |  | completed | "Cognition Therapeutics, Inc. (NASDAQ: CGTX), clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the first quarter ended March" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1455365/000110465926057186/tm2613845d1_ex99-1.htm)) |
| May 7, 2026 | [Enliven Therapeutics, Inc. earnings report](https://sec-api.dev/companies/elvn/catalysts) | ELVN |  | completed | "Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672619/000119312526211921/elvn-ex99_1.htm)) |
| May 7, 2026 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/sln-ex99_1.htm)) |
| May 7, 2026 | [Black Diamond Therapeutics, Inc. earnings report](https://sec-api.dev/companies/bdtx/catalysts) | BDTX |  | completed | "Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000015/bdtx-exhibit991_q12026.htm)) |
| May 7, 2026 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "HARMONY BIOSCIENCES REPORTS Q1 FINANCIAL RESULTS AND CONFIRMS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION; REINFORCES 2026 STRATEGIC PRIORITIES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d1.htm)) |
| May 7, 2026 | [Ginkgo Bioworks Holdings, Inc. earnings report](https://sec-api.dev/companies/dna/catalysts) | DNA |  | completed | "Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830214/000162828026032093/ex991earningspr.htm)) |
| May 7, 2026 | [CAD-1005 earnings report](https://sec-api.dev/pdufa/cad-1005) | CVKD |  | completed | "(Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting continued progress in its CAD-1005 program for HIT." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937993/000121390026053075/ea028937701ex99-1.htm)) |
| May 7, 2026 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "XERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000027/exh991q12026earningsrelease.htm)) |
| May 7, 2026 | [Evommune, Inc. earnings report](https://sec-api.dev/companies/evmn/catalysts) | EVMN |  | completed | "Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2044725/000119312526211934/evmn-ex99_1.htm)) |
| May 7, 2026 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126019573/ef20072739_ex99-1.htm)) |
| May 7, 2026 | [Zymeworks Inc. earnings report](https://sec-api.dev/companies/zyme/catalysts) | ZYME |  | completed | "Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000033/ex991q12026_earningsxrelea.htm)) |
| May 7, 2026 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000011/tmb-20260507xex99d1.htm)) |
| May 7, 2026 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "(NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2026 financial results, business achievements, and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/tm2613648d1_ex99-1.htm)) |
| May 7, 2026 | [Phio Pharmaceuticals Corp. earnings report](https://sec-api.dev/companies/phio/catalysts) | PHIO |  | completed | "Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1533040/000143774926015590/ex_940071.htm)) |
| May 7, 2026 | [Annexon, Inc. earnings report](https://sec-api.dev/companies/annx/catalysts) | ANNX |  | completed | "Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526211863/annx-ex99_1.htm)) |
| May 7, 2026 | [Entrada Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trda/catalysts) | TRDA |  | completed | "Entrada Therapeutics Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000027/entradatherapeuticsreports.htm)) |
| May 7, 2026 | [PROTHENA CORP PUBLIC LTD CO earnings report](https://sec-api.dev/companies/prta/catalysts) | PRTA |  | completed | "Prothena Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1559053/000155905326000016/exhibit991q12026earningsre.htm)) |
| May 7, 2026 | [Zipalertinib NDA/BLA acceptance](https://sec-api.dev/pdufa/zipalertinib) | CGEM |  | completed | ""Further, with our partner Taiho, we announced FDA acceptance of our first NDA submission, representing a significant milestone for Cullinan Therapeutics and bringing zipalertinib meaningfully closer to being available for patients, with a PDUFA date of February 27, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm)) |
| May 7, 2026 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/vera-ex99_1.htm)) |
| May 7, 2026 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, May 7, 2026 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000086/exhibit991-2026q110xqpr.htm)) |
| May 7, 2026 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312526210286/amlx-ex99_1.htm)) |
| May 7, 2026 | [COLLEGIUM PHARMACEUTICAL, INC earnings report](https://sec-api.dev/companies/coll/catalysts) | COLL |  | completed | "Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1267565/000162828026031694/coll-2026x03x31xex99x1.htm)) |
| May 7, 2026 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000062/ex991pressreleaseq12026.htm)) |
| May 7, 2026 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000035/crbu-20260507xexx991.htm)) |
| May 7, 2026 | [ENTR-601 topline data readout](https://sec-api.dev/pdufa/entr-601) | TRDA |  | completed, positive | "BOSTON, May 7, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-44-201 clinical study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000027/entradatherapeuticscohort1.htm)) |
| May 7, 2026 | [Tectonic Therapeutic, Inc. earnings report](https://sec-api.dev/companies/tecx/catalysts) | TECX |  | completed | "Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1681087/000119312526212069/tecx-ex99_1.htm)) |
| May 7, 2026 | [NATURES SUNSHINE PRODUCTS INC earnings report](https://sec-api.dev/companies/natr/catalysts) | NATR |  | completed | "Nature's Sunshine Reports Strong First Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/275053/000162828026032330/natrq12026earningsrelease.htm)) |
| May 7, 2026 | [Lipocine Inc. earnings report](https://sec-api.dev/companies/lpcn/catalysts) | LPCN |  | completed | "Announces Financial Results for the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1535955/000149315226021638/ex99-1.htm)) |
| May 7, 2026 | [IN8BIO, INC. earnings report](https://sec-api.dev/companies/inab/catalysts) | INAB |  | completed | "IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1740279/000119312526212128/inab-ex99_1.htm)) |
| May 7, 2026 | [Cingulate Inc. complete response letter (CRL)](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed, complete response letter | "From time to time, beginning on May 7, 2026, Avondale may redeem a portion of the 2025 Note, not to exceed an amount of $660,000 per month; and provided that we have not previously received a "complete response letter" from the FDA with respect to CTx-1301, we may defer up to two redemptions for up to thirty (30) days each." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1862150/000149315226037606/form10-q.htm)) |
| May 7, 2026 | [MBX Biosciences, Inc. earnings report](https://sec-api.dev/companies/mbx/catalysts) | MBX |  | completed | "MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776111/000119312526210825/mbx-ex99_1.htm)) |
| May 7, 2026 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000019/amrx-q12026ex991.htm)) |
| May 7, 2026 | [ARROWHEAD PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/arwr/catalysts) | ARWR |  | completed | "Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000087940726000045/arwr-202605078kex991.htm)) |
| May 7, 2026 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "SHANGHAI & CAMBRIDGE, Mass., May 7, 2026 -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2026, along with recent product highlights and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026031624/zlab-202657x8kex991.htm)) |
| May 7, 2026 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES FIRST QUARTER FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm)) |
| May 7, 2026 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000031/amph-20260507xex99d1.htm)) |
| May 7, 2026 | [ImageneBio, Inc. earnings report](https://sec-api.dev/companies/ima/catalysts) | IMA |  | completed | "ImageneBio Reports First Quarter 2026 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835579/000119312526211935/d151394dex991.htm)) |
| May 7, 2026 | [Aligos Therapeutics, Inc. earnings report](https://sec-api.dev/companies/algs/catalysts) | ALGS |  | completed | "Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1799448/000117184326003156/exh_991.htm)) |
| May 7, 2026 | [Anitocabtagene autoleucel NDA/BLA acceptance](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD |  | completed | "•Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm)) |
| May 7, 2026 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526210298/glue-ex99_1.htm)) |
| May 7, 2026 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "(Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2026 and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926056783/tm2613489d1_ex99-1.htm)) |
| May 7, 2026 | [ASSEMBLY BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/asmb/catalysts) | ASMB |  | completed | "Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1426800/000119312526211922/asmb-ex99_1.htm)) |
| May 7, 2026 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465926057171/nxtc-20260507xex99d1.htm)) |
| May 7, 2026 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000038/q12026pr.htm)) |
| May 7, 2026 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d1.htm)) |
| May 7, 2026 | [Korro Bio, Inc. earnings report](https://sec-api.dev/companies/krro/catalysts) | KRRO |  | completed | "Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703647/000119312526210291/krro-ex99_1.htm)) |
| May 7, 2026 | [MARAVAI LIFESCIENCES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/mrvi/catalysts) | MRVI |  | completed | "MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1823239/000182323926000022/exhibit991-q12026.htm)) |
| May 7, 2026 | [Stoke Therapeutics, Inc. earnings report](https://sec-api.dev/companies/stok/catalysts) | STOK |  | completed | "Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1623526/000119312526212020/stok-ex99_1.htm)) |
| May 7, 2026 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm)) |
| May 7, 2026 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926015621/ex_938051.htm)) |
| May 7, 2026 | [INTENSITY THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ints/catalysts) | INTS |  | completed | "Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000047/ints20260507ex99120260331p.htm)) |
| May 7, 2026 | [Xenon Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/xene/catalysts) | XENE |  | completed | "Xenon Reports Q1 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526211843/xene-ex99_1.htm)) |
| May 7, 2026 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2026 RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390026053369/ea028961101ex99-1.htm)) |
| May 7, 2026 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184326003154/exh_991.htm)) |
| May 7, 2026 | [Neumora Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nmra/catalysts) | NMRA |  | completed | "Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1885522/000119312526210310/nmra-ex99_1.htm)) |
| May 7, 2026 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126019430/ef20072589_ex99-1.htm)) |
| May 7, 2026 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2026 results and recent business performance." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465926056656/tm267094d1_ex99-1.htm)) |
| May 7, 2026 | [Werewolf Therapeutics, Inc. earnings report](https://sec-api.dev/companies/howl/catalysts) | HOWL |  | completed | "Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000011/a03312026ex991.htm)) |
| May 7, 2026 | [ROCKWELL MEDICAL, INC. earnings report](https://sec-api.dev/companies/rmti/catalysts) | RMTI |  | completed | "Rockwell Medical Announces First Quarter 2026 Results and Additional 2026 Guidance with Focus on Profitability" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1041024/000162828026031629/a2025q1-26xearningsxpr.htm)) |
| May 7, 2026 | [Jade Biosciences, Inc. earnings report](https://sec-api.dev/companies/jbio/catalysts) | JBIO |  | completed | "Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312526211973/d108669dex991.htm)) |
| May 7, 2026 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000119312526210283/nams-ex99_1.htm)) |
| May 7, 2026 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526209789/gyre-ex99_1.htm)) |
| May 7, 2026 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926056669/acrs-20260507xex99d1.htm)) |
| May 7, 2026 | [Rapport Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rapp/catalysts) | RAPP |  | completed | "BOSTON and SAN DIEGO, May 7, 2026 -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter ending March 31, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/rapp-ex99_1.htm)) |
| May 7, 2026 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports First-Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000025/exhibit991-1q26earningsrel.htm)) |
| May 7, 2026 | [Climb Bio, Inc. earnings report](https://sec-api.dev/companies/clym/catalysts) | CLYM |  | completed | "Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768446/000119312526210295/clym-ex99_1.htm)) |
| May 7, 2026 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "Filana Therapeutics Reports Q1 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184326003119/exh_991.htm)) |
| May 7, 2026 | [REVELATION BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/revb/catalysts) | REVB |  | completed | "Revelation Biosciences, Inc. Announces Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810560/000119312526212064/revb-ex99_1.htm)) |
| May 7, 2026 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000119312526211964/janx-ex99_1.htm)) |
| May 7, 2026 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926015586/ex_958542.htm)) |
| May 7, 2026 | [Zura Bio Ltd earnings report](https://sec-api.dev/companies/zura/catalysts) | ZURA |  | completed | "Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855644/000162828026031701/zura-20260507xex991.htm)) |
| May 7, 2026 | [LEXICON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/lxrx/catalysts) | LXRX |  | completed | "The Woodlands, Texas, May 7, 2026 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2026, and provided an update on key corporate milestones and accomplishments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282226000098/pressreleaseearningsq105-0.htm)) |
| May 7, 2026 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312526210615/whwk-ex99_1.htm)) |
| May 7, 2026 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062026000048/exhibit991_q12026earningsr.htm)) |
| May 7, 2026 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312526211867/lona-ex99_1.htm)) |
| May 7, 2026 | [4D Molecular Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fdmt/catalysts) | FDMT |  | completed | "4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526211904/fdmt-ex99_1.htm)) |
| May 7, 2026 | [Beam Therapeutics Inc. earnings report](https://sec-api.dev/companies/beam/catalysts) | BEAM |  | completed | "Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745999/000119312526210299/beam-ex99_1.htm)) |
| May 7, 2026 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000030/q12026earningsrelease_ex991.htm)) |
| May 7, 2026 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm)) |
| May 7, 2026 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_1.htm)) |
| May 7, 2026 | [Alector, Inc. earnings report](https://sec-api.dev/companies/alec/catalysts) | ALEC |  | completed | "Alector Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1653087/000119312526211918/alec-ex99_1.htm)) |
| May 7, 2026 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828026031713/ex991earningsreleaseq12026.htm)) |
| May 7, 2026 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000162828026031643/sttk_q12026earningspr.htm)) |
| May 7, 2026 | [Aardvark Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aard/catalysts) | AARD |  | completed | "Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/ck0001774857-ex99_1.htm)) |
| May 7, 2026 | [Generate Biomedicines, Inc. earnings report](https://sec-api.dev/companies/genb/catalysts) | GENB |  | completed | "Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2100782/000119312526209899/ck0002100782-ex99_1.htm)) |
| May 7, 2026 | [CHARLES RIVER LABORATORIES INTERNATIONAL, INC. earnings report](https://sec-api.dev/companies/crl/catalysts) | CRL |  | completed | "WILMINGTON, MA, May 7, 2026 - Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1100682/000110068226000036/crl1q26earningsrelease.htm)) |
| May 7, 2026 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Reports First Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/tm2613721d1_ex99-1.htm)) |
| May 7, 2026 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036126019538/ef20072552_ex99-1.htm)) |
| May 7, 2026 | [Kodiak Sciences Inc. earnings report](https://sec-api.dev/companies/kod/catalysts) | KOD |  | completed | "Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000119312526211811/kod-ex99_1.htm)) |
| May 7, 2026 | [Zoetis Inc. earnings report](https://sec-api.dev/companies/zts/catalysts) | ZTS |  | completed | "Zoetis Announces First Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1555280/000155528026000021/exhibit99q12026.htm)) |
| May 7, 2026 | [CytomX Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctmx/catalysts) | CTMX |  | completed | "CytomX Therapeutics Announces Q1 2026 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501989/000119312526211920/ctmx-ex99_1.htm)) |
| May 7, 2026 | [VLA15 topline data readout](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | completed | "NCT05634811 (Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-21 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05634811?tab=results)) |
| May 7, 2026 | [ARD-101 primary completion](https://sec-api.dev/pdufa/ard-101) | AARD | Hyperphagia; Prader-Willi Syndrome | withdrawn | "NCT06828861 (ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-05-07 (ACTUAL); Lead Sponsor Aardvark Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06828861)) |
| May 8, 2026 | [Entera Bio Ltd. earnings report](https://sec-api.dev/companies/entx/catalysts) | ENTX |  | completed | "Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638097/000117891326002455/exhibit_99-1.htm)) |
| May 8, 2026 | [BioAffinity Technologies, Inc. earnings report](https://sec-api.dev/companies/biaf/catalysts) | BIAF |  | completed | "Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1712762/000149315226021861/ex99-1.htm)) |
| May 8, 2026 | [BioAge Labs, Inc. earnings report](https://sec-api.dev/companies/bioa/catalysts) | BIOA |  | completed | "BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1709941/000119312526213472/bioa-ex99_1.htm)) |
| May 8, 2026 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "2026 - Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the first quarter ended March 31, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926057524/tm2613977d1_ex99-1.htm)) |
| May 8, 2026 | [KIORA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/kprx/catalysts) | KPRX |  | completed | "Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000048/ex991-pressreleasemarch312.htm)) |
| May 8, 2026 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000049/anip-20260508xexx991.htm)) |
| May 8, 2026 | [AlloNK (AB-101) interim data readout](https://sec-api.dev/pdufa/ab-101) | ARTV | debilitating autoimmune diseases, today | completed, positive | "(Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced positive initial clinical data from ongoing clinical trials evaluating AlloNK® (also known as AB-101) in combination with rituximab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160dex992.htm)) |
| May 8, 2026 | [ALX ONCOLOGY HOLDINGS INC earnings report](https://sec-api.dev/companies/alxo/catalysts) | ALXO |  | completed | "ALX Oncology Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810182/000119312526213380/alxo-ex99_1.htm)) |
| May 8, 2026 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526213440/ck0001991792-ex99_1.htm)) |
| May 8, 2026 | [Boundless Bio, Inc. earnings report](https://sec-api.dev/companies/bold/catalysts) | BOLD |  | completed | "SAN DIEGO, May 8, 2026 - Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782303/000119312526213269/bold-ex99_1.htm)) |
| May 8, 2026 | [INTEGRATED BIOPHARMA INC earnings report](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | completed | "HILLSIDE, NEW JERSEY (May 8, 2026) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/ex_958786.htm)) |
| May 8, 2026 | [TRUXIMA® (rituximab) interim data readout](https://sec-api.dev/pdufa/rituximab) | ARTV |  | completed, positive | "On May 8, 2026, we announced positive initial clinical data from ongoing clinical trials evaluating AlloNK in combination with rituximab." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1817241/000119312526338029/artv-20260630.htm)) |
| May 8, 2026 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160dex991.htm)) |
| May 8, 2026 | [Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc) | ARGX |  | completed, approved | "BLA761304 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260508, review_priority PRIORITY; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22)) |
| May 8, 2026 | [Vyvgart (efgartigimod alfa) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX |  | completed, approved | "BLA761195 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20260508, review_priority PRIORITY; sponsor_name ARGENX BV; product VYVGART (EFGARTIGIMOD ALFA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761195%22)) |
| May 8, 2026 | [OG-6219 topline data readout](https://sec-api.dev/pdufa/og-6219) | OGN | Endometriosis | completed | "NCT05560646 (A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Organon and Co; Results First Posted 2026-05-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05560646?tab=results)) |
| May 10, 2026 | [VYVGART (efgartigimod) PDUFA date](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | scheduled | "These data support our supplemental regulatory submission to expand VYVGART into the seronegative population, which was accpeted for priority review with an expected PDUFA target action date of May 10, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm)) |
| May 10, 2026 | [Zai Lab Ltd PDUFA date](https://sec-api.dev/companies/zlab/catalysts) | ZLAB | with acetylcholine receptor antibody | scheduled | "-Seronegative generalized myasthenia gravis (sn-gMG): In January 2026, the FDA accepted for Priority Review a supplemental Biologics License Application (sBLA) for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) sn-gMG, with a Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226x8kex991.htm)) |
| May 10, 2026 | [MoonLake Immunotherapeutics earnings report](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | completed | "MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000005/moonlake-pressreleasexq120.htm)) |
| May 11, 2026 | [Aura Biosciences, Inc. earnings report](https://sec-api.dev/companies/aura/catalysts) | AURA |  | completed | "Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501796/000119312526216743/aura-ex99_1.htm)) |
| May 11, 2026 | [Azora Therapeutics, Inc. (DE) earnings report](https://sec-api.dev/companies/azr/catalysts) | AZR |  | completed | "Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1513525/000121390026054219/ea028994701ex99-1.htm)) |
| May 11, 2026 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465926058638/avbp-20260511xex99d1.htm)) |
| May 11, 2026 | [Bicara Therapeutics Inc. earnings report](https://sec-api.dev/companies/bcax/catalysts) | BCAX |  | completed | "Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026033135/pressrelease-q12026.htm)) |
| May 11, 2026 | [Elicio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eltx/catalysts) | ELTX |  | completed | "Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000041/eltx1q26pr.htm)) |
| May 11, 2026 | [EDP-978 trial start](https://sec-api.dev/pdufa/edp-978) | ENTA |  | completed | "In April, the Company announced the first participant was dosed in a randomized, double-blind, placebo-controlled, first-in-human Phase 1 clinical trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/enta-ex99_1.htm)) |
| May 11, 2026 | [Perspective Therapeutics, Inc. earnings report](https://sec-api.dev/companies/catx/catalysts) | CATX |  | completed | "SEATTLE - May 11, 2026 - Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/728387/000119312526216777/catx-ex99_1.htm)) |
| May 11, 2026 | [PLIANT THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/plrx/catalysts) | PLRX |  | completed | "Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000088/plrx-2026511xexx991.htm)) |
| May 11, 2026 | [ABCL635 earnings report](https://sec-api.dev/pdufa/abcl635) | ABCL |  | completed | "VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2026 and positive interim results from the Phase 1 portion of its ongoing Phase 1/2 clinical trial of ABCL635." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000027/q12026earningspressrelease.htm)) |
| May 11, 2026 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS First QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926016881/ex_908797.htm)) |
| May 11, 2026 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "N.C., May 11, 2026 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the first quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465926058234/tm2614109d1_ex99-1.htm)) |
| May 11, 2026 | [Biomea Fusion, Inc. earnings report](https://sec-api.dev/companies/bmea/catalysts) | BMEA |  | completed | "Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840439/000119312526217037/bmea-ex99_1.htm)) |
| May 11, 2026 | [Turn Therapeutics Inc. earnings report](https://sec-api.dev/companies/ttrx/catalysts) | TTRX |  | completed | "Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial results for the three months ended March 31, 2026, and provided corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023016/000121390026054480/ea028985601ex99-1.htm)) |
| May 11, 2026 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/enta-ex99_1.htm)) |
| May 11, 2026 | [Erasca, Inc. earnings report](https://sec-api.dev/companies/eras/catalysts) | ERAS |  | completed | "Erasca Reports First Quarter 2026 Business Updates and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761918/000119312526216739/eras-ex99_1.htm)) |
| May 11, 2026 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/rani-ex99_1.htm)) |
| May 11, 2026 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312526215720/dyn-ex99_1.htm)) |
| May 11, 2026 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465926058636/ganx-20260511xex99d1.htm)) |
| May 11, 2026 | [Tonix Pharmaceuticals Holding Corp. earnings report](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937126010487/ex99-01.htm)) |
| May 11, 2026 | [Septerna, Inc. earnings report](https://sec-api.dev/companies/sepn/catalysts) | SEPN |  | completed | "Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1984086/000119312526216723/sepn-ex99_1.htm)) |
| May 11, 2026 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000119312526215838/agen-ex99_1.htm)) |
| May 11, 2026 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000035/a991q126pressrelease.htm)) |
| May 11, 2026 | [Aktis Oncology, Inc. earnings report](https://sec-api.dev/companies/akts/catalysts) | AKTS |  | completed | "Aktis Oncology Reports Financial Results and Business Highlights For First Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2035832/000119312526216716/ck0002035832-ex99_1.htm)) |
| May 11, 2026 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/ex991q120268-k.htm)) |
| May 11, 2026 | [HARROW, INC. earnings report](https://sec-api.dev/companies/hrow/catalysts) | HROW |  | completed | "Announces First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1360214/000149315226022227/ex99-1.htm)) |
| May 11, 2026 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/kynb-ex99_1.htm)) |
| May 11, 2026 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/chrs-20260511xex99d1.htm)) |
| May 11, 2026 | [Metagenomi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mgx/catalysts) | MGX |  | completed | "Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785279/000119312526216763/mgx-ex99_1.htm)) |
| May 11, 2026 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/lxeo-ex99_1.htm)) |
| May 11, 2026 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/hrtx-ex99_1.htm)) |
| May 11, 2026 | [Ordastobart interim data readout](https://sec-api.dev/pdufa/ordastobart) | INBX |  | completed, positive | "On May 11, 2026, Inhibrx announced positive interim results from its randomized, first-line Phase 2 portion of the HexAgon study." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000020/inhibrx-20260511.htm)) |
| May 11, 2026 | [AN2 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/antx/catalysts) | ANTX |  | completed | "AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1880438/000119312526216752/antx-ex99_1.htm)) |
| May 11, 2026 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/tm2614295d1_ex99-1.htm)) |
| May 11, 2026 | [Sana Biotechnology, Inc. earnings report](https://sec-api.dev/companies/sana/catalysts) | SANA |  | completed | "Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770121/000119312526216758/sana-ex99_1.htm)) |
| May 11, 2026 | [Eikon Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eikn/catalysts) | EIKN |  | completed | "Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1861123/000119312526216744/eikn-ex99_1.htm)) |
| May 11, 2026 | [Itacitinib primary completion](https://sec-api.dev/pdufa/itacitinib) | INCY |  | withdrawn | "NCT04640025 (A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-11 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04640025)) |
| May 11, 2026 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Inducible Urticaria | completed | "NCT05976243 (A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-11 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05976243)) |
| May 11, 2026 | [AZD9550 primary completion](https://sec-api.dev/pdufa/azd9550) | AZN | Obesity or Overweight | completed | "NCT06862791 (A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-11 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06862791)) |
| May 11, 2026 | [Flu mrna (formulation a) primary completion](https://sec-api.dev/pdufa/flu-mrna-formulation-a) | GSK | Influenza, Human | completed | "NCT07121192 (A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-11 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07121192)) |
| May 12, 2026 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/armp-20260512xex99d1.htm)) |
| May 12, 2026 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000119312526219361/bolt-ex99_1.htm)) |
| May 12, 2026 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Reports First Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/tm2614225d1_ex99-1.htm)) |
| May 12, 2026 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000009/sls-202605128xkexhibit991.htm)) |
| May 12, 2026 | [Allogene Therapeutics, Inc. earnings report](https://sec-api.dev/companies/allo/catalysts) | ALLO |  | completed | "Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737287/000162828026034583/allo-20260331xexx991q126.htm)) |
| May 12, 2026 | [PALI-2108 earnings report](https://sec-api.dev/pdufa/pali-2108) | PALI |  | completed | "Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000011/pali-ex99_1.htm)) |
| May 12, 2026 | [Nkarta, Inc. earnings report](https://sec-api.dev/companies/nktx/catalysts) | NKTX |  | completed | "Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000012/nktx-ex99_1.htm)) |
| May 12, 2026 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/ea029027701ex99-1.htm)) |
| May 12, 2026 | [Zentalis Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/zntl/catalysts) | ZNTL |  | completed | "Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1725160/000172516026000041/zntlq12026pressrelease.htm)) |
| May 12, 2026 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports FIRST Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/kura-ex99_1.htm)) |
| May 12, 2026 | [Neurogene earnings report](https://sec-api.dev/pdufa/neurogene) | NGNE |  | completed | "Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000038/ngne_1qye26earningsrelease.htm)) |
| May 12, 2026 | [C4 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cccc/catalysts) | CCCC |  | completed | "C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662579/000162828026033861/cccc-20260512xexx991.htm)) |
| May 12, 2026 | [Prelude Therapeutics Inc earnings report](https://sec-api.dev/companies/prld/catalysts) | PRLD |  | completed | "Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1678660/000119312526218162/prld-ex99_1.htm)) |
| May 12, 2026 | [RELMADA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/rlmd/catalysts) | RLMD |  | completed | "Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1553643/000121390026055164/ea029041401ex99-1.htm)) |
| May 12, 2026 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512xex99d1.htm)) |
| May 12, 2026 | [LUMRYZ (lumryz) topline data readout](https://sec-api.dev/pdufa/lumryz) | ALKS | idiopathic hypersomnia | completed, positive | "On May 12, 2026, the Company announced positive topline results from REVITALYZSM, a double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ® (sodium oxybate) extended-release oral suspension compared to placebo in adults with idiopathic hypersomnia." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526218150/alks-20260512.htm)) |
| May 12, 2026 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, May 12, 2026 (Globe NewsWire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the first quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526218142/olma-ex99_1.htm)) |
| May 12, 2026 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926059392/tm2614169d1_ex99-1.htm)) |
| May 12, 2026 | [Veradermics, Inc earnings report](https://sec-api.dev/companies/mane/catalysts) | MANE |  | completed | "Veradermics Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000016/ex991q126earnings.htm)) |
| May 12, 2026 | [Connect Biopharma Holdings Ltd earnings report](https://sec-api.dev/companies/cntb/catalysts) | CNTB |  | completed | "Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000019/cntbq12026earningsrelease.htm)) |
| May 12, 2026 | [MAXCYTE, INC. earnings report](https://sec-api.dev/companies/mxct/catalysts) | MXCT |  | completed | "MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1287098/000110465926059399/mxct-20260512xex99d1.htm)) |
| May 12, 2026 | [Emavusertib earnings report](https://sec-api.dev/pdufa/emavusertib) | CRIS |  | completed | "LEXINGTON, Mass., May 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000059/a1q26earningspressrelease.htm)) |
| May 12, 2026 | [Imatinib earnings report](https://sec-api.dev/pdufa/imatinib) | IKT |  | completed | ""Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended March 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/d119997dex991.htm)) |
| May 12, 2026 | [IBio, Inc. earnings report](https://sec-api.dev/companies/ibio/catalysts) | IBIO |  | completed | "Exhibit 99.1 iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1420720/000110465926059408/ibio-20260512xex99d1.htm)) |
| May 12, 2026 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/d24879dex991.htm)) |
| May 12, 2026 | [Xilio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/xlo/catalysts) | XLO |  | completed | "Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840233/000119312526218194/xlo-ex99_1.htm)) |
| May 12, 2026 | [Kyverna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kytx/catalysts) | KYTX |  | completed | "Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1994702/000119312526219377/kytx-ex99_1.htm)) |
| May 12, 2026 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315226022401/ex99-1.htm)) |
| May 12, 2026 | [Coya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/coya/catalysts) | COYA |  | completed | "Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835022/000119312526218198/coya-ex99_1.htm)) |
| May 12, 2026 | [Corbus Pharmaceuticals Holdings, Inc. earnings report](https://sec-api.dev/companies/crbp/catalysts) | CRBP |  | completed | "Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1595097/000119312526218250/crbp-ex99_1.htm)) |
| May 12, 2026 | [YCANTH (cantharidin) trial start](https://sec-api.dev/pdufa/cantharidin) | VRCA | common warts | completed | "Further, last December the first patient was dosed in the first trial (COVE-2) of the global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts, and we are happy to announce achievement of over 50% of the current targeted enrollment in the trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/d152529dex991.htm)) |
| May 12, 2026 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026033875/q12026earningsrelease.htm)) |
| May 12, 2026 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/pmvp-ex99_1.htm)) |
| May 12, 2026 | [Lineage Cell Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lctx/catalysts) | LCTX |  | completed | "LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/876343/000119312526219421/lctx-ex99_1.htm)) |
| May 12, 2026 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/maze-ex99_1.htm)) |
| May 12, 2026 | [LB PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lbrx/catalysts) | LBRX |  | completed | "LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1691082/000119312526219529/d134118dex991.htm)) |
| May 12, 2026 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000162828026033868/abos-20260512xexx991.htm)) |
| May 12, 2026 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/d152529dex991.htm)) |
| May 12, 2026 | [BridgeBio Oncology Therapeutics, Inc. earnings report](https://sec-api.dev/companies/bbot/catalysts) | BBOT |  | completed | "BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1869105/000119312526219801/bbot-ex99_1.htm)) |
| May 12, 2026 | [Atea Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/avir/catalysts) | AVIR |  | completed | "Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1593899/000119312526219507/d12234dex991.htm)) |
| May 12, 2026 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Immunome Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/imnm-ex99_1.htm)) |
| May 12, 2026 | [Sionna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sion/catalysts) | SION |  | completed | "Sionna Therapeutics Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2036042/000162828026033870/sion1q26earningsrelease_fi.htm)) |
| May 12, 2026 | [PepGen Inc. earnings report](https://sec-api.dev/companies/pepg/catalysts) | PEPG |  | completed | "PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835597/000119312526219424/pepg-ex99_1.htm)) |
| May 12, 2026 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/ck0001534133-ex99_1.htm)) |
| May 12, 2026 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000162828026033856/ird-2026512xex991.htm)) |
| May 12, 2026 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926059380/capr-20260512xex99d1.htm)) |
| May 12, 2026 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000029/q12026-ex991earningsrelease.htm)) |
| May 12, 2026 | [VEPPANU (vepdegestrant) FDA approval](https://sec-api.dev/pdufa/vepdegestrant) | ARVN | ESR1m, ER+/HER2- advanced breast cancer - | completed, approved | "- Announced FDA Approval of VEPPANU™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026033875/q12026earningsrelease.htm)) |
| May 12, 2026 | [TENAX THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tenx/catalysts) | TENX |  | completed | "Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/34956/000119312526218224/d91737dex991.htm)) |
| May 12, 2026 | [ANAPTYSBIO, INC earnings report](https://sec-api.dev/companies/anab/catalysts) | ANAB |  | completed | "Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-ex99_1.htm)) |
| May 12, 2026 | [Vireo Growth Inc. earnings report](https://sec-api.dev/companies/vreof/catalysts) | VREOF |  | completed | "Vireo Growth Inc. Announces First Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771706/000110465926059005/vreof-20260512xex99d1.htm)) |
| May 2026 | [Sinovac pcv13 primary completion](https://sec-api.dev/pdufa/sinovac-pcv13) | SVA | Pneumococcal Infectious Disease | delayed | "NCT06617715 (Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-05-12 (ESTIMATED); Lead Sponsor Sinovac Life Sciences Co., Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06617715)) |
| May 12, 2026 | [Tebapivat primary completion](https://sec-api.dev/pdufa/tebapivat) | AGIO | Sickle Cell Disease | completed | "NCT06924970 (A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-12 (ACTUAL); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06924970)) |
| May 12, 2026 | [BGB-45035 primary completion](https://sec-api.dev/pdufa/bgb-45035) | ONC | Rheumatoid Arthritis | withdrawn | "NCT07100938 (A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-12 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07100938)) |
| May 13, 2026 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/ea028858101ex99-1.htm)) |
| May 13, 2026 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312526220569/d114190dex991.htm)) |
| May 13, 2026 | [SPRUCE BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/sprb/catalysts) | SPRB |  | completed | "Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1683553/000119312526220648/sprb-ex99_1.htm)) |
| May 13, 2026 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774926016718/ex_941648.htm)) |
| May 13, 2026 | [Acrivon Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrv/catalysts) | ACRV |  | completed | "Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781174/000119312526221626/acrv-ex99_1.htm)) |
| May 13, 2026 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/tngx-ex99_1.htm)) |
| May 13, 2026 | [Upstream Bio, Inc. earnings report](https://sec-api.dev/companies/upb/catalysts) | UPB |  | completed | "Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022626/000119312526220578/upb-ex99_1.htm)) |
| May 13, 2026 | [PDS Biotechnology Corp earnings report](https://sec-api.dev/companies/pdsb/catalysts) | PDSB |  | completed | "PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472091/000114036126020934/ef20073195_ex99-1.htm)) |
| May 13, 2026 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "13, 2026 - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results for the first quarter ending March 31, 2026, and provided corporate and regulatory updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/tm2614433d1_ex99-1.htm)) |
| May 13, 2026 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "BRANFORD, Conn. - May 13, 2026 — Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000029/aztrpressrelease3312026-ex.htm)) |
| May 13, 2026 | [Prestige Consumer Healthcare Inc. earnings report](https://sec-api.dev/companies/pbh/catalysts) | PBH |  | completed | "TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-May 13, 2026-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1295947/000129594726000013/exhibit991fy26-q4earningsr.htm)) |
| May 13, 2026 | [Xenetic Biosciences, Inc. earnings report](https://sec-api.dev/companies/xbio/catalysts) | XBIO |  | completed | "Reports First Quarter 2026 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534525/000168316826003766/xenetic_ex9901.htm)) |
| May 13, 2026 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, May 13, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the first quarter ended March 31, 2026, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/plx-20260513xex99d1.htm)) |
| May 13, 2026 | [Arbutus Biopharma Corp earnings report](https://sec-api.dev/companies/abus/catalysts) | ABUS |  | completed | "Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/exh_991.htm)) |
| May 13, 2026 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774926016760/ex_962420.htm)) |
| May 13, 2026 | [VTv Therapeutics Inc. earnings report](https://sec-api.dev/companies/vtvt/catalysts) | VTVT |  | completed | "Exhibit 99.1 vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641489/000164148926000019/vtvt-20260331xexx991pressr.htm)) |
| May 13, 2026 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000019/ino-33126x8kex991.htm)) |
| May 13, 2026 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/q12026pressrelease.htm)) |
| May 13, 2026 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000011/exhibit991-earningsrelease.htm)) |
| May 13, 2026 | [BeyondSpring Inc. earnings report](https://sec-api.dev/companies/bysi/catalysts) | BYSI |  | completed | "BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677940/000117184326003344/exh_991.htm)) |
| May 13, 2026 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312526221658/eldn-ex99_1.htm)) |
| May 13, 2026 | [PRECIGEN, INC. earnings report](https://sec-api.dev/companies/pgen/catalysts) | PGEN |  | completed | "Precigen Reports First Quarter 2026 Financial Results and Business" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1356090/000095010326007158/dp246650_ex9901.htm)) |
| May 13, 2026 | [Adicet Bio, Inc. earnings report](https://sec-api.dev/companies/acet/catalysts) | ACET |  | completed | "Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000036/acet-ex99_1.htm)) |
| May 13, 2026 | [AYTU BIOPHARMA, INC earnings report](https://sec-api.dev/companies/aytu/catalysts) | AYTU |  | completed | "Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1385818/000143774926016717/ex_918589.htm)) |
| May 13, 2026 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312526220638/tyra-ex99_1.htm)) |
| May 13, 2026 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports First Quarter 2026 Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/ex99-1.htm)) |
| May 13, 2026 | [Aprea Therapeutics, Inc. earnings report](https://sec-api.dev/companies/apre/catalysts) | APRE |  | completed | "Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513xex99d1.htm)) |
| May 13, 2026 | [Fasenra (benralizumab) label expansion decision](https://sec-api.dev/pdufa/benralizumab) | AZN |  | completed, approved | "BLA761070 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20260513, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product FASENRA (BENRALIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761070%22)) |
| May 13, 2026 | [DYADIC INTERNATIONAL INC earnings report](https://sec-api.dev/companies/dyai/catalysts) | DYAI |  | completed | "ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213809/000149315226022727/ex99-1.htm)) |
| May 13, 2026 | [IMMUNIC, INC. earnings report](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed | "IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000119380526000593/e665461_ex99-1.htm)) |
| May 13, 2026 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312526220691/fate-ex99_1.htm)) |
| May 13, 2026 | [Avalo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/avtx/catalysts) | AVTX |  | completed | "Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000032/ex-9911q2026earningsrelease.htm)) |
| May 13, 2026 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "CAMBRIDGE, Mass., May 13, 2026 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/d147628dex991.htm)) |
| May 13, 2026 | [Longeveron Inc. earnings report](https://sec-api.dev/companies/lgvn/catalysts) | LGVN |  | completed | "LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended March 31, 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1721484/000121390026055806/ea029043601ex99-1.htm)) |
| May 13, 2026 | [Century Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ipsc/catalysts) | IPSC |  | completed | "Century Therapeutics Reports First Quarter Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850119/000110465926059824/tm2614312d1_ex99-1.htm)) |
| May 13, 2026 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000040/exhibit99-1earningspressre.htm)) |
| May 13, 2026 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312526221595/eq-ex99_1.htm)) |
| May 13, 2026 | [TALPHERA, INC. earnings report](https://sec-api.dev/companies/tlph/catalysts) | TLPH |  | completed | "Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427925/000143774926016724/ex_960711.htm)) |
| May 13, 2026 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_ex99-1.htm)) |
| May 13, 2026 | [Altimmune, Inc. earnings report](https://sec-api.dev/companies/alt/catalysts) | ALT |  | completed | "Altimmune Announces First Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm)) |
| May 13, 2026 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | SNY | Colitis Ulcerative | completed | "NCT05731128 (A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-13 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05731128)) |
| May 13, 2026 | [WAINUA (eplontersen) primary completion](https://sec-api.dev/pdufa/eplontersen) | AZN | Transthyretin Amyloid Cardiomyopathy | completed | "NCT06194825 (EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-13 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06194825)) |
| May 13, 2026 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Severe Eosinophilic Asthma | completed | "NCT06465485 (STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-13 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465485)) |
| May 13, 2026 | [Lebrikizumab primary completion](https://sec-api.dev/pdufa/lebrikizumab) | LLY | Atopic Hand and Foot Dermatitis | completed | "NCT06921759 (A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-13 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06921759)) |
| May 13, 2026 | [BEQALZI™ (sonrotoclax) FDA approval](https://sec-api.dev/pdufa/sonrotoclax) | ONC |  | completed, approved | "Beqalzi \| sonrotoclax \| 5/13/2026 \| To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| May 14, 2026 | [First Tracks Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/trax/catalysts) | TRAX |  | completed | "First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2091349/000119312526224124/trax-ex99_1.htm)) |
| May 14, 2026 | [Edesa Biotech, Inc. earnings report](https://sec-api.dev/companies/edsa/catalysts) | EDSA |  | completed | "Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1540159/000117184326003429/exh_991.htm)) |
| May 14, 2026 | [Keros Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kros/catalysts) | KROS |  | completed | "Keros Therapeutics Reports Recent First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000029/exhibit991q12026.htm)) |
| May 14, 2026 | [Dogwood Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dwtx/catalysts) | DWTX |  | completed | "Dogwood Therapeutics Announces First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818844/000110465926060747/dwtx-20260514xex99d1.htm)) |
| May 14, 2026 | [Briquilimab earnings report](https://sec-api.dev/pdufa/briquilimab) | JSPR |  | completed | "- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1788028/000121390026056596/ea029079201ex99-1.htm)) |
| May 14, 2026 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774926017063/ex_935862.htm)) |
| May 14, 2026 | [Karyopharm Therapeutics Inc. earnings report](https://sec-api.dev/companies/kpti/catalysts) | KPTI |  | completed | "Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1503802/000119312526222808/kpti-ex99_1.htm)) |
| May 14, 2026 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774926017070/ex_962125.htm)) |
| May 14, 2026 | [SANGAMO THERAPEUTICS, INC earnings report](https://sec-api.dev/companies/sgmoq/catalysts) | SGMOQ |  | completed | "RICHMOND, California, May 14, 2026 - Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2026 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001233/000162828026035061/exhibit-991051426.htm)) |
| May 14, 2026 | [AEON Biopharma, Inc. earnings report](https://sec-api.dev/companies/aeon/catalysts) | AEON |  | completed | "AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000041/aeon-20260514xex99d1.htm)) |
| May 14, 2026 | [Valion Bio, Inc. earnings report](https://sec-api.dev/companies/vbio/catalysts) | VBIO |  | completed | "Valion Bio Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787740/000143774926017082/ex_941939.htm)) |
| May 14, 2026 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465926061208/fbio-20260514xex99.htm)) |
| May 14, 2026 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, IL, May 14, 2026 - Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced first quarter 2026 financial results and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774926016981/ex_962976.htm)) |
| May 14, 2026 | [Calidi Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/cldi/catalysts) | CLDI |  | completed | "Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855485/000149315226023094/ex99-1.htm)) |
| May 14, 2026 | [Tempest Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tpst/catalysts) | TPST |  | completed | "Tempest Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1544227/000119312526224156/tpst-ex99_1.htm)) |
| May 14, 2026 | [Benitec Biopharma Inc. earnings report](https://sec-api.dev/companies/bntc/catalysts) | BNTC |  | completed | "HAYWARD, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its third fiscal quarter ended March 31, 2026, and provided a review of recent clinical study results and anticipated upcoming regulatory and clinical study milestones." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1808898/000119312526222879/bntc-ex99_1.htm)) |
| May 14, 2026 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000009/alms-20260514xex99d1.htm)) |
| May 14, 2026 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/d120795dex991.htm)) |
| May 14, 2026 | [Pelthos Therapeutics Inc. earnings report](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed | "Pelthos Therapeutics Announces First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000071/pths-pressreleasex20250514.htm)) |
| May 14, 2026 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526222892/cadl-ex99_1.htm)) |
| May 14, 2026 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm)) |
| May 14, 2026 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526222768/rgnx-ex99_1.htm)) |
| May 14, 2026 | [CV Sciences, Inc. earnings report](https://sec-api.dev/companies/cvsi/catalysts) | CVSI |  | completed | "CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1510964/000119312526349136/cvsi-ex99_1.htm)) |
| May 14, 2026 | [Cingulate Inc. earnings report](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed | "Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226022881/ex99-1.htm)) |
| May 14, 2026 | [MeiraGTx Holdings plc earnings report](https://sec-api.dev/companies/mgtx/catalysts) | MGTX |  | completed | "LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1735438/000110465926060726/mgtx-20260514xex99d1.htm)) |
| May 14, 2026 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/stro-ex99_1.htm)) |
| May 14, 2026 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "CORMEDIX THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000020/crmd_q12026earningspr.htm)) |
| May 14, 2026 | [RGX-202 topline data readout](https://sec-api.dev/pdufa/rgx-202) | RGNX |  | completed, positive | "REGENXBIO today announced positive topline results from the pivotal Phase III AFFINITY DUCHENNE trial of RGX-202, including primary endpoint (n=30 at Week 12), interim safety (n=31), and interim functional data (n=9 at 12 months):1 o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526222768/rgnx-ex99_1.htm)) |
| May 14, 2026 | [Cardiff Oncology, Inc. earnings report](https://sec-api.dev/companies/crdf/catalysts) | CRDF |  | completed | "Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213037/000121303726000013/crdf-ex99_1.htm)) |
| May 14, 2026 | [Serina Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ser/catalysts) | SER |  | completed | "Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000036/ser-20260514xex991_earning.htm)) |
| May 14, 2026 | [Ovaprene (ovaprene) earnings report](https://sec-api.dev/pdufa/ovaprene) | DARE |  | completed | "Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update Your publication date and time will appear here. \| Source: Daré Bioscience, Inc. Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women's Health Week." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000025/a260514q12026earningsupd.htm)) |
| May 14, 2026 | [Arazlo® (tazarotene) earnings report](https://sec-api.dev/pdufa/tazarotene) | GRI |  | completed | "GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429326000046/ex991_pressreleaseq126earn.htm)) |
| May 14, 2026 | [Pyxis Oncology, Inc. earnings report](https://sec-api.dev/companies/pyxs/catalysts) | PYXS |  | completed | "Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782223/000119312526222818/pyxs-ex99_1.htm)) |
| May 14, 2026 | [CYPHERPUNK TECHNOLOGIES INC. earnings report](https://sec-api.dev/companies/cyph/catalysts) | CYPH |  | completed | "MA - May 14, 2026 - Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the first quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509745/000110465926060686/tm2614533d1_ex99-1.htm)) |
| May 14, 2026 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926061148/mtva-20260514xex99d1.htm)) |
| May 14, 2026 | [Biologics earnings report](https://sec-api.dev/pdufa/biologics) | HCWB |  | completed | "FL - May 14, 2026 - HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune disease, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three months ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828673/000149315226023122/ex99-1.htm)) |
| May 14, 2026 | [ELUTIA INC. earnings report](https://sec-api.dev/companies/elut/catalysts) | ELUT |  | completed | "Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708527/000110465926061150/elut-20260514xex99d1.htm)) |
| May 14, 2026 | [MapLight Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mplt/catalysts) | MPLT |  | completed | "MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526224067/mplt-ex99_1.htm)) |
| May 14, 2026 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Reports First Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465926060693/tm2614602d1_ex99-1.htm)) |
| May 14, 2026 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/exhibit99103312026.htm)) |
| May 14, 2026 | [SENTI-202 earnings report](https://sec-api.dev/pdufa/senti-202) | SNTI |  | completed | "Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000162828026034834/ex991sntiq126earningsrelea.htm)) |
| May 14, 2026 | [Larimar Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | completed | "Bala Cynwyd, PA, May 14, 2026 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2026 operating and financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/lrmr-ex99_1.htm)) |
| May 14, 2026 | [Atrium Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rna/catalysts) | RNA |  | completed | "Atrium Therapeutics Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2093101/000119312526224238/d82207dex991.htm)) |
| May 14, 2026 | [AUCATZYL (obecabtagene autoleucel) earnings report](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed | "Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates May 14, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000058/autlex-991pr140526.htm)) |
| May 14, 2026 | [Cabaletta Bio, Inc. earnings report](https://sec-api.dev/companies/caba/catalysts) | CABA |  | completed | "Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm)) |
| May 14, 2026 | [LINZESS® (linaclotide) topline data readout](https://sec-api.dev/pdufa/linaclotide) | ABBV | Functional Constipation (FC); Chronic Idiopathic Constipation (CIC) | completed | "NCT05652205 (A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-05-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05652205?tab=results)) |
| May 14, 2026 | [Dtg/3tc topline data readout](https://sec-api.dev/pdufa/dtg-3tc) | GSK | HIV; HIV Infections | completed | "NCT05911360 (A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-23 (ACTUAL); Lead Sponsor ViiV Healthcare; Results First Posted 2026-05-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05911360?tab=results)) |
| May 14, 2026 | [GSK4527226 primary completion](https://sec-api.dev/pdufa/gsk4527226) | GSK | Alzheimer's Disease | withdrawn | "NCT06079190 (Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-14 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079190)) |
| May 14, 2026 | [Rocatinlimab primary completion](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Asthma | withdrawn | "NCT06376045 (A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-14 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06376045)) |
| May 14, 2026 | [Praxis Precision Medicines, Inc. primary completion](https://sec-api.dev/companies/prax/catalysts) | PRAX | Focal Seizure | completed | "NCT06999902 (Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-05-14 (ACTUAL); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06999902)) |
| May 15, 2026 | [Traws Pharma, Inc. earnings report](https://sec-api.dev/companies/traw/catalysts) | TRAW |  | completed | "Provides Business Highlights and Reports Q1 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1130598/000110465926061771/tm2614707d1_ex99-1.htm)) |
| May 15, 2026 | [Ensysce Biosciences, Inc. earnings report](https://sec-api.dev/companies/ensc/catalysts) | ENSC |  | completed | "Biosciences Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1716947/000149315226023810/ex99-1.htm)) |
| May 15, 2026 | [Outlook Therapeutics, Inc. earnings report](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed | "Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926062865/tm2614868d1_ex99-1.htm)) |
| May 15, 2026 | [Moleculin Biotech, Inc. earnings report](https://sec-api.dev/companies/mbrx/catalysts) | MBRX |  | completed | "Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1659617/000143774926017226/ex_963393.htm)) |
| May 15, 2026 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000055/imrx-20260505xexx991.htm)) |
| May 15, 2026 | [MiNK Therapeutics, Inc. earnings report](https://sec-api.dev/companies/inkt/catalysts) | INKT |  | completed | "MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840229/000119312526225369/inkt-ex99_1.htm)) |
| May 15, 2026 | [Citius Pharmaceuticals, Inc. trial start](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Announced positive topline results from two investigator-initiated Phase 1 studies, including:" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/ea029103701ex99-1.htm)) |
| May 15, 2026 | [Faeth Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fth/catalysts) | FTH |  | completed | "Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1829802/000119312526225323/d125741dex991.htm)) |
| May 15, 2026 | [Pulmatrix, Inc. earnings report](https://sec-api.dev/companies/pulm/catalysts) | PULM |  | completed | "Announces First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1574235/000149315226023367/ex99-1.htm)) |
| May 15, 2026 | [TuHURA Biosciences, Inc./NV earnings report](https://sec-api.dev/companies/hura/catalysts) | HURA |  | completed | "TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498382/000119312526227204/hura-ex99_1.htm)) |
| May 15, 2026 | [Lantern Pharma Inc. earnings report](https://sec-api.dev/companies/ltrn/catalysts) | LTRN |  | completed | "Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/ex99-1.htm)) |
| May 15, 2026 | [BioXcel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed | "(Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today provided a business update and reported financial results for the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm)) |
| May 15, 2026 | [Instil Bio, Inc. earnings report](https://sec-api.dev/companies/til/catalysts) | TIL |  | completed | "Instil Bio Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789769/000178976926000044/q1-26er.htm)) |
| May 15, 2026 | [LYMPHIR (lymphir) trial start](https://sec-api.dev/pdufa/lymphir) | CTOR |  | completed | "Announced positive topline results from two investigator-initiated Phase 1 studies evaluating LYMPHIR in combination settings, including:" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm)) |
| May 15, 2026 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm)) |
| May 15, 2026 | [Enveric Biosciences, Inc. earnings report](https://sec-api.dev/companies/envb/catalysts) | ENVB |  | completed | "Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/ex99-1.htm)) |
| May 15, 2026 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March 31, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465926062766/tm2614771d1_ex99-1.htm)) |
| May 15, 2026 | [PROKIDNEY CORP. earnings report](https://sec-api.dev/companies/prok/catalysts) | PROK |  | completed | "ProKidney Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850270/000119312526225848/prok-ex99_1.htm)) |
| May 15, 2026 | [Annovis Bio, Inc. earnings report](https://sec-api.dev/companies/anvs/catalysts) | ANVS |  | completed | "Provides Corporate Updates and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465926062451/tm2614822d1_ex99-1.htm)) |
| May 15, 2026 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported business and financial results for the fiscal second quarter ended March 31, 2026, and provided a business update, including progress at its majority-owned subsidiary, Citius" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/ea029103701ex99-1.htm)) |
| May 15, 2026 | [Baxfendy (baxdrostat) FDA approval](https://sec-api.dev/pdufa/baxdrostat) | AZN | To treat hypertension in combination with other antihypertensive drugs | completed, approved | "Baxfendy \| baxdrostat \| 5/15/2026 \| To treat hypertension in combination with other antihypertensive drugs" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| May 15, 2026 | [ATYR PHARMA INC earnings report](https://sec-api.dev/companies/atyr/catalysts) | ATYR |  | completed | "Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-ex99_1.htm)) |
| May 15, 2026 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036126021496/ef20073003_ex99-1.htm)) |
| May 15, 2026 | [BioCardia, Inc. earnings report](https://sec-api.dev/companies/bcda/catalysts) | BCDA |  | completed | "BioCardia Reports First Quarter 2026 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/925741/000143774926017222/ex_963539.htm)) |
| May 15, 2026 | [Indaptus Therapeutics, Inc. earnings report](https://sec-api.dev/companies/indp/catalysts) | INDP |  | completed | "Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1857044/000149315226023344/ex99-1.htm)) |
| May 15, 2026 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/spry-ex99_1.htm)) |
| May 15, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | completed | "NCT03847428 (Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-15 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03847428)) |
| May 15, 2026 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Bipolar Disorder, Manic | completed | "NCT06462612 (Study of Lumateperone in the Treatment of Patients With Bipolar Mania): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-15 (ACTUAL); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06462612)) |
| May 15, 2026 | [Acasunlimab primary completion](https://sec-api.dev/pdufa/acasunlimab) | GMAB |  | withdrawn | "NCT06984328 (Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-15 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-09-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06984328)) |
| May 18, 2026 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000036/goss-20260518xexx991xearni.htm)) |
| May 18, 2026 | [Silexion Therapeutics Corp earnings report](https://sec-api.dev/companies/slxn/catalysts) | SLXN |  | completed | "Silexion Therapeutics Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002761/exhibit_99-1.htm)) |
| May 18, 2026 | [Scienture Holdings, Inc. earnings report](https://sec-api.dev/companies/scnx/catalysts) | SCNX |  | completed | "Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382574/000149315226025062/ex99-1.htm)) |
| May 18, 2026 | [NEONC TECHNOLOGIES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/nthi/catalysts) | NTHI |  | completed | "NeOnc Provides Business Update and Reports Q1 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1979414/000182912626005421/neonctechnologies_ex99-1.htm)) |
| May 18, 2026 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/ex99-1.htm)) |
| May 18, 2026 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926017637/ex_964814.htm)) |
| May 18, 2026 | [Nucala (mepolizumab) topline data readout](https://sec-api.dev/pdufa/mepolizumab) | GSK | Asthma | completed | "NCT04718389 (A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-14 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04718389?tab=results)) |
| May 18, 2026 | [Sigvotatug vedotin primary completion](https://sec-api.dev/pdufa/sigvotatug-vedotin) | PFE | Carcinoma, Non-Small-Cell Lung | completed | "NCT06012435 (A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-18 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06012435)) |
| May 18, 2026 | [Bl1107 low dose primary completion](https://sec-api.dev/pdufa/bl1107) | BLCO | Glaucoma | completed | "NCT07168902 (Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-18 (ACTUAL); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07168902)) |
| May 18, 2026 | [Zynyz (retifanlimab-dlwr) label expansion decision](https://sec-api.dev/pdufa/retifanlimab-dlwr) | INCY |  | completed, approved | "BLA761334 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20260518, review_priority STANDARD; sponsor_name INCYTE CORP; product ZYNYZ (RETIFANLIMAB-DLWR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761334%22)) |
| May 19, 2026 | [Tecfidera (dimethyl fumarate) topline data readout](https://sec-api.dev/pdufa/dimethyl) | BIIB | Relapsing-Remitting Multiple Sclerosis | completed | "NCT02283853 (Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-08 (ACTUAL); Lead Sponsor Biogen; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02283853?tab=results)) |
| May 19, 2026 | [TAK-771 topline data readout](https://sec-api.dev/pdufa/tak-771) | TAK | Primary Immunodeficiency Diseases (PID) | completed | "NCT05513586 (A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05513586?tab=results)) |
| May 19, 2026 | [Oral evo756 300 mg qd topline data readout](https://sec-api.dev/pdufa/oral-evo756) | EVMN | Chronic Inducible Urticaria | completed | "NCT06603220 (A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Evommune, Inc.; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06603220?tab=results)) |
| May 20, 2026 | [Roivant Sciences Ltd. earnings report](https://sec-api.dev/companies/roiv/catalysts) | ROIV |  | completed | "Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000060/q4fy2025roivantearningsrel.htm)) |
| May 20, 2026 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/exhibit9912026520.htm)) |
| May 20, 2026 | [Jaguar Health, Inc. earnings report](https://sec-api.dev/companies/jagx/catalysts) | JAGX |  | completed | "("Jaguar" or the "Company") today reported its consolidated first-quarter 2026 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585608/000119312526232722/d143790dex991.htm)) |
| May 20, 2026 | [Lysergide tartrate primary completion](https://sec-api.dev/pdufa/lysergide) | DFTX | Major Depressive Disorder | completed | "NCT06941844 (A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-20 (ACTUAL); Lead Sponsor Definium Therapeutics US, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06941844)) |
| May 20, 2026 | [Venclexta (venetoclax) label expansion decision](https://sec-api.dev/pdufa/venetoclax) | ABBV |  | completed, approved | "NDA208573 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20260520, review_priority STANDARD; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22)) |
| May 21, 2026 | [Hemab Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/coag/catalysts) | COAG |  | completed | "Hemab Therapeutics Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2114044/000119312526233375/d102408dex991.htm)) |
| May 21, 2026 | [LINZESS® (linaclotide) label expansion decision](https://sec-api.dev/pdufa/linaclotide) | ABBV |  | completed, approved | "NDA202811 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20260521, review_priority PRIORITY; sponsor_name ABBVIE; product LINZESS (LINACLOTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202811%22)) |
| May 22, 2026 | [Hepcludex (bulevirtide-gmod) FDA approval](https://sec-api.dev/pdufa/bulevirtide-gmod) | GILD |  | completed, approved | "Hepcludex \| bulevirtide-gmod \| 5/22/2026 \| To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| May 22, 2026 | [Venglustat (gz402671) primary completion](https://sec-api.dev/pdufa/venglustat-gz402671) | SNY | Fabry Disease | completed | "NCT05280548 (A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-22 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05280548)) |
| May 22, 2026 | [XPOVIO® (selinexor) primary completion](https://sec-api.dev/pdufa/selinexor) | KPTIQ | Endometrial Cancer | completed | "NCT05611931 (Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-22 (ACTUAL); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05611931)) |
| May 22, 2026 | [Zavzpret ® (zavegepant) topline data readout](https://sec-api.dev/pdufa/zavegepant) | PFE | Migraine | completed | "NCT05989048 (A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05989048?tab=results)) |
| May 22, 2026 | [Ruxolitinib cream topline data readout](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Atopic Dermatitis | completed | "NCT06238817 (A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Incyte Corporation; Results First Posted 2026-05-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06238817?tab=results)) |
| May 22, 2026 | [Hypericin primary completion](https://sec-api.dev/pdufa/hypericin) | SNGX | CTCL/ Mycosis Fungoides; CTCL; Mycosis Fungoides | withdrawn | "NCT06470451 (Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-05-22 (ACTUAL); Lead Sponsor Soligenix." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06470451)) |
| May 23, 2026 | [BAT1706 primary completion](https://sec-api.dev/pdufa/bat1706) | ONC | Advanced Malignancies | completed | "NCT04164199 (Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-23 (ACTUAL); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04164199)) |
| May 23, 2026 | [Hmpl-760 planned dose 1 primary completion](https://sec-api.dev/pdufa/hmpl-760-planned) | HCM | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | "NCT06601504 (Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-23 (ACTUAL); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06601504)) |
| May 23, 2026 | [Uptravi (selexipag) label expansion decision](https://sec-api.dev/pdufa/selexipag) | JNJ |  | completed, approved | "NDA207947 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20260523, review_priority PRIORITY; sponsor_name ACTELION; product UPTRAVI (SELEXIPAG)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207947%22)) |
| May 24, 2026 | [LEQEMBI (lecanemab) PDUFA date](https://sec-api.dev/pdufa/lecanemab) | BIIB |  | delayed | "•In January 2026 the FDA accepted for review the supplemental BLA for LEQEMBI subcutaneous autoinjector, LEQEMBI IQLIK, for a weekly starting dose, with a PDUFA action date of May 24, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504526000045/biib-20260331.htm)) |
| May 25, 2026 | [Adi-peg20 primary completion](https://sec-api.dev/pdufa/adi-peg20) | PII | Soft Tissue Sarcoma | withdrawn | "NCT05712694 (Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-05-25 (ACTUAL); Lead Sponsor Polaris Group." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05712694)) |
| May 25, 2026 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT06143046 (A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-25 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06143046)) |
| May 25, 2026 | [ICOTYDE (icotrokinra) primary completion](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Arthritis, Psoriatic | completed | "NCT06878404 (A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-25 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06878404)) |
| May 26, 2026 | [Kailera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klra/catalysts) | KLRA |  | completed | "Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2096997/000119312526239362/ck0002096997-ex99_1.htm)) |
| May 26, 2026 | [Certepetide topline data readout](https://sec-api.dev/pdufa/certepetide) | LSTA | Cholangiocarcinoma; Gallbladder Cancer; Gallbladder Carcinoma | completed | "NCT05712356 (A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-05 (ACTUAL); Lead Sponsor Lisata Therapeutics, Inc.; Results First Posted 2026-05-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05712356?tab=results)) |
| May 26, 2026 | [AZD6234 primary completion](https://sec-api.dev/pdufa/azd6234) | AZN | Endocrinology; Diabetes, Type II; Obesity | completed | "NCT06851858 (Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-26 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06851858)) |
| May 27, 2026 | [APHEXDA® (motixafortide) trial start](https://sec-api.dev/pdufa/motixafortide) | BLRX | Glioblastoma | completed | "- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498403/000117891326002934/exhibit_1.htm)) |
| May 27, 2026 | [BRIUMVI® (ublituximab) topline data readout](https://sec-api.dev/pdufa/ublituximab) | TGTX | relapsing forms of multiple sclerosis | completed, positive | "NEW YORK, May 27, 2026 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI® (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (RMS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/ex_968837.htm)) |
| May 27, 2026 | [Ribitol NDA/BLA acceptance](https://sec-api.dev/pdufa/ribitol) | BBIO |  | completed | "PALO ALTO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) with Priority" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_ex99-1.htm)) |
| May 27, 2026 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Hepatocellular Carcinoma; Liver Cancer | completed | "NCT03383458 (A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-27 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03383458)) |
| May 27, 2026 | [Scemblix (asciminib) topline data readout](https://sec-api.dev/pdufa/asciminib) | NVS | Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | completed | "NCT05456191 (A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-05-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05456191?tab=results)) |
| May 27, 2026 | [Vocabria (cabotegravir sodium) primary completion](https://sec-api.dev/pdufa/cabotegravir) | GSK | HIV Infections | completed | "NCT05996471 (A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-27 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05996471)) |
| May 27, 2026 | [Decnupaz (pivekimab sunirine-pvzy) FDA approval](https://sec-api.dev/pdufa/pivekimab-sunirine-pvzy) | ABBV | To treat adults with blastic plasmacytoid dendritic cell neoplasm | completed, approved | "Decnupaz \| pivekimab sunirine-pvzy \| 5/27/2026 \| To treat adults with blastic plasmacytoid dendritic cell neoplasmDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| May 28, 2026 | [Vyome Holdings, Inc earnings report](https://sec-api.dev/companies/hind/catalysts) | HIND |  | completed | "Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427570/000121390026062458/ea029264301ex99-1.htm)) |
| May 28, 2026 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-53 (Efficacy): submission_status AP, submission_status_date 20260528, review_priority STANDARD; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| May 28, 2026 | [Tremfya (guselkumab) label expansion decision](https://sec-api.dev/pdufa/guselkumab) | JNJ |  | completed, approved | "BLA761061 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20260528, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22)) |
| May 28, 2026 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | Pre-Exposure Prophylaxis of HIV Infection | completed | "NCT06513312 (Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06513312)) |
| May 28, 2026 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | completed | "NCT06641076 (Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06641076)) |
| May 28, 2026 | [Xiidra (lifitegrast) primary completion](https://sec-api.dev/pdufa/lifitegrast) | BLCO | Dry Eye Disease | completed | "NCT07128628 (A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07128628)) |
| May 28, 2026 | [VRDN-003 primary completion](https://sec-api.dev/pdufa/vrdn-003) | VRDN | Thyroid Eye Disease | completed | "NCT07155668 (A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07155668)) |
| May 29, 2026 | [Afrezza (afrezza) FDA approval](https://sec-api.dev/pdufa/afrezza) | MNKD |  | completed, approved | "Received FDA approval of Afrezza on May 29, 2026 for use in children and adolescents ages 6 and older living with diabetes" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/mnkd-ex99_1.htm)) |
| May 29, 2026 | [Afrezza (afrezza) PDUFA date](https://sec-api.dev/pdufa/afrezza) | MNKD |  | completed, approved | "o sBLA for Afrezza® in pediatric population accepted for FDA review; PDUFA date of May 29, 2026 o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/mnkd-ex99_1.htm)) |
| May 29, 2026 | [MANNKIND CORP PDUFA date](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | scheduled | "The sBLA has been assigned a PDUFA target action date of May 29, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/899460/000119312526208916/mnkd-20260331.htm)) |
| May 29, 2026 | [Afrezza (insulin recombinant human) label expansion decision](https://sec-api.dev/pdufa/insulin-recombinant-human) | MNKD |  | completed, approved | "BLA022472 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20260529, review_priority STANDARD; sponsor_name MANNKIND; product AFREZZA (INSULIN RECOMBINANT HUMAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA022472%22)) |
| May 29, 2026 | [Pemazyre (pemigatinib) primary completion](https://sec-api.dev/pdufa/pemigatinib) | INCY | Endometrial Cancer | completed | "NCT04463771 (Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-29 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04463771)) |
| May 29, 2026 | [Tdv topline data readout](https://sec-api.dev/pdufa/tdv) | TAK | Healthy Volunteers | completed | "NCT06060067 (A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-05 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06060067?tab=results)) |
| May 29, 2026 | [Evo756, dose 1 primary completion](https://sec-api.dev/pdufa/evo756) | EVMN | Chronic Spontaneous Urticaria | completed | "NCT06873516 (Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-29 (ACTUAL); Lead Sponsor Evommune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06873516)) |
| May 29, 2026 | [Release (release) complete response letter (CRL)](https://sec-api.dev/pdufa/release) | CING |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA220283_20260529_Redacted.pdf%22)) |
| May 30, 2026 | [OP-3136 interim data readout](https://sec-api.dev/pdufa/op-3136) | OLMA |  | scheduled | "As previously announced, Olema will present initial clinical data from the Phase 1 study of OP-3136 in a poster presentation on May 30, 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/olma-ex99_1.htm)) |
| May 31, 2026 | [Indegene NDA/BLA acceptance](https://sec-api.dev/pdufa/indegene) | CING |  | completed | "2025, the FDA accepted for review the NDA for CTx-1301 and assigned a PDUFA target action date of May 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm)) |
| May 31, 2026 | [Indegene PDUFA date](https://sec-api.dev/pdufa/indegene) | CING |  | completed, complete response letter | "2025, the FDA accepted for review the NDA for CTx-1301 and assigned a PDUFA target action date of May 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm)) |
| May 31, 2026 | [Cingulate Inc. PDUFA date](https://sec-api.dev/companies/cing/catalysts) | CING |  | scheduled | "New Drug Application (NDA) for CTx-1301 and had assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/ex99-1.htm)) |
| May 2026 | [APG-115 primary completion](https://sec-api.dev/pdufa/apg-115) | AAPG | T-Prolymphocytic Leukemia; Non-Hodgkins Lymphoma | delayed | "NCT04496349 (A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-05-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04496349)) |
| May 31, 2026 | [Sonesitatug vedotin primary completion](https://sec-api.dev/pdufa/sonesitatug-vedotin) | AZN | Gastric Cancer; Gastroesophageal Junction Cancer | completed | "NCT06346392 (AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-31 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06346392)) |

Other months: https://sec-api.dev/fda-calendar/2026-04 , https://sec-api.dev/fda-calendar/2026-06. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates May 2026: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2026-05

```bibtex
@misc{secapidev_fda_calendar_2026_05_20261116,
  title        = {PDUFA dates May 2026: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2026-05}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2026_05_20261116","title":"PDUFA dates May 2026: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2026-05","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
